<div id="readability-page-1"><p><span>Haemonetics (NYSE:HAE - Get Free Report)</span> was downgraded by equities research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Sunday.</p><p>A number of other brokerages also recently commented on HAE. Needham &amp; Company LLC lifted their target price on shares of Haemonetics from $68.00 to $78.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, November 7th. Citigroup reduced their price target on shares of Haemonetics from $78.00 to $64.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, October 7th. BTIG Research  reiterated a &#34;buy&#34; rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, November 21st. JPMorgan Chase &amp; Co. raised their target price on Haemonetics from $62.00 to $74.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday. Finally, Raymond James Financial  reaffirmed an &#34;outperform&#34; rating and issued a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. One equities research analyst  has rated the stock with a Strong Buy rating, eight have issued  a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $80.90.</p><p><b>View Our Latest Report on HAE</b></p><h2>Haemonetics Trading Down 1.2%</h2><p>Shares of Haemonetics stock opened at $83.46 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The stock's 50 day simple moving average is $65.38 and its 200-day simple moving average is $64.42. The stock has a market cap of $3.91 billion, a P/E ratio of 24.40, a P/E/G ratio of 1.58 and a beta of 0.30. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. </p><p>Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter last year, the business posted $1.12 earnings per share. The firm's revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.  Analysts predict that  Haemonetics will post 4.55 EPS for the current fiscal year. </p><h2>Institutional Trading of Haemonetics</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of HAE. CIBC Private Wealth Group LLC lifted its position in shares of  Haemonetics by 69.3% during the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 448 shares in the last quarter.  CIBC Bancorp USA Inc. purchased a new stake in  Haemonetics during the 3rd quarter worth approximately $251,000.  Danske Bank A S acquired a new stake in  Haemonetics during the 3rd quarter worth approximately $665,000.  Caitong International Asset Management Co. Ltd boosted its position in  Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 837 shares during the period.  Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of  Haemonetics by 3.7% in the third quarter. CANADA LIFE ASSURANCE Co now owns 35,438 shares of the medical instruments supplier's stock worth $1,706,000 after acquiring an additional 1,266 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Haemonetics Company Profile</h2> (Get Free Report)<p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Haemonetics</li><li>Stock Splits, Do They Really Impact Investors?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>Golden Cross Stocks: Pattern, Examples and Charts </li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>How to Invest in Small Cap Stocks </li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2><p>Before you consider Haemonetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wall Street Zen downgraded Haemonetics (NYSE:HAE) from a "buy" to a "hold" rating. Despite this, other analysts have varied opinions, with some maintaining a "buy" rating and adjusting target prices. Haemonetics reported strong quarterly earnings, surpassing estimates, and has a positive outlook for FY 2026. Institutional investors have been actively trading the stock, which is currently trading at $83.46. The company specializes in medical products and solutions, particularly in plasma collection systems.</p>

Haemonetics (NYSE:HAE) Stock Rating Lowered by Wall Street Zen